Rhone-Poulenc Rorer's new quinolone antibiotic, sparfloxacin, has been launched in France, under the tradename Zagam. This is the second market for the drug; it was first approved last year in Japan under the tradename Spara by original developer Dainippon.
Zagam will be marketed in France by R-PR subsidiary Laboratoires Specia. The initial indications for the drug are community-acquired pneumonia, exacerbations of chronic obstructive bronchopulmonary infections and purulent acute sinusitis. The drug is priced at 218.3 French francs, ($41.13) for a course of six tablets, and is reimbursed at the 65% level.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze